Clinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/11/2025 ,inter alia, to consider and approve To consider and approve ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Ltd has informed BSE that its Board of Directors will meet on Saturday, November 22, 2025 at 11:30 AM at its registered office in Navi Mumbai. The key item on the agenda is to consider and approve the formation of a new subsidiary to be named 'Medicarenx Multispeciality Hospital Private Limited' and to subscribe to its memorandum. The company is currently a small listed entity (scrip code 544220) in the laboratory services space, and this move signals an expansion into multispeciality hospital services. Any other business items may also be taken up with the Chair's permission. The intimation has been made under SEBI LODR Regulations 29 and 30.
For shareholders, this represents a diversification move from laboratory services into hospital/healthcare delivery, which could open new revenue streams but also adds execution and capital deployment risk. The stock may see some interest given the change in business direction, though the small-cap nature means low liquidity could amplify price moves.